Carbachol in cataract surgery.
H Beasley, A R Borgmann, T O McDonald...
https://pubmed.ncbi.nlm.nih.gov/5660015/Actively Recruiting
Led by University of Missouri-Columbia · Updated on 2025-10-15
72
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are studying cat bites to the hand and forearm to understand the best way to prevent infections after such injuries. Cat bites can introduce bacteria deep into tissues, leading to serious infections. The study evaluates whether different durations of antibiotic treatment or no antibiotics at all affect infection rates. This is a randomized, controlled, double-blind clinical trial involving adult patients presenting within 24 hours of a cat bite without signs of active infection or recent antibiotic use. Participants in this trial will be randomly assigned to one of three groups a placebo group receiving capsules twice daily for five days a group receiving amoxicillin-clavulanate or, for those allergic to penicillin, ciprofloxacin plus clindamycin, for one day with placebo for the remaining days and a group receiving the same antibiotics for five days. Alongside medication, standard wound care including cleaning, removal of foreign bodies, and dressing will be provided. The study uses infrared and digital cameras to monitor wounds. During the study, infection signs will be checked at multiple points day 0, day 2, day 7 plus or minus 2 days, day 14 plus or minus 2 days, and day 30 plus or minus 2 days. Researchers will assess infection rates, side effects, disability using Quick Disabilities of Arm, Shoulder and Hand QuickDASH scores, and quality of life using the HAND Questionnaire HAND-Q. Participants will undergo physical exams, vital sign measurements, laboratory tests, and imaging as part of routine care and study assessments. The study will correlate bite locations with infection outcomes.
CONDITIONS
CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)
S
Stephen H Colbert, MD
K
Kevin M Klifto, DO, PharmD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Missouri-Columbia
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Amoxicillin‑clavulanate (1‑day) | Placebo (no antibiotic) | Amoxicillin‑clavulanate (5‑days) |
|---|---|---|---|
| What it is | A one‑day course of oral amoxicillin‑clavulanate | No prophylactic antibiotic; placebo control | A five‑day course of oral amoxicillin‑clavulanate |
| Role in trial | Investigational short‑duration prophylaxis group | Control group allowing baseline infection assessment | Investigational longer‑duration prophylaxis group consistent with current practice |
| Purpose | Assess whether a single‑day antibiotic course reduces post‑bite infection | Evaluate infection risk without antibiotic prophylaxis | Assess whether a five‑day antibiotic course reduces post‑bite infection |
| Administration or procedure | Oral amoxicillin‑clavulanate twice daily for one day | Oral placebo twice daily matching antibiotic schedule | Oral amoxicillin‑clavulanate twice daily for five days |
| Support in current practice | Short‑duration prophylaxis mirrors typical 3–5‑day courses but shorter; efficacy under investigation | Guidelines recommend prophylaxis in high‑risk cat bites, so placebo represents withholding standard care being tested | Five‑day antibiotic course matches common current prophylaxis durations |
| Important risks | Short antibiotic exposure but risk of side effects like gastrointestinal upset or allergy exists | No antibiotic means risk of untreated infection remains | Longer exposure increases risk of antibiotic‑related adverse effects such as diarrhea or allergy |
| Limitations | One‑day course may be too short to prevent infection if typical duration is longer | Withholding antibiotic may increase infection risk in high‑risk wounds | Standard practice but may contribute to antibiotic overuse or resistance |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 24 hours before treatment
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 to 5 days
Participants receive either antibiotic prophylaxis or placebo by mouth for 1 to 5 days and undergo wound management including irrigation and debridement as needed.
1 baseline visit and 1 follow-up visit on Day 2
Duration - Up to 30 days
Participants are monitored for signs of infection, disability, and adverse effects after treatment ends.
Visits on Day 7, Day 14, and Day 30
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
H Beasley, A R Borgmann, T O McDonald...
https://pubmed.ncbi.nlm.nih.gov/5660015/R M Elenbaas, W K McNabney, W A Robinson
https://pubmed.ncbi.nlm.nih.gov/6696302/Kyra Sierakowski, Nicola R Dean, Andrea L Pusic...
https://pubmed.ncbi.nlm.nih.gov/30898824/Leon S Benson, Sara L Edwards, Adam P Schiff...
https://pubmed.ncbi.nlm.nih.gov/16516744/Sophia Kwo, Jayant P Agarwal, Steven Meletiou
https://pubmed.ncbi.nlm.nih.gov/20006917/Bryan Coburn, Baldwin Toye, Prasad Rawte...
https://pubmed.ncbi.nlm.nih.gov/23403420/P L Hudak, P C Amadio, C Bombardier
https://pubmed.ncbi.nlm.nih.gov/8773720/Albert Lloret, Herman Egberink, Diane Addie...
https://pubmed.ncbi.nlm.nih.gov/23813817/I Medeiros, H Saconato
https://pubmed.ncbi.nlm.nih.gov/11406003/Brooke Bregman, Sally Slavinski
https://pubmed.ncbi.nlm.nih.gov/22379219/University of Missouri-Columbia
Lead Sponsor